Melanoma Therapeutics: a Literature Review

Overview

Journal J Biomed Res

Specialty General Medicine

Date 2022 Mar 9

PMID 35260531

Authors

Pavan Kumar Dhanyamraju

Trupti N Patel

Affiliations

Soon will be listed here.

Abstract

Melanoma is a relentless type of skin cancer which involves myriad signaling pathways which regulate many cellular processes. This makes melanoma difficult to treat, especially when identified late. At present, therapeutics include chemotherapy, surgical resection, biochemotherapy, immunotherapy, photodynamic and targeted approaches. These interventions are usually administered as either a single-drug or in combination, based on tumor location, stage, and patients' overall health condition. However, treatment efficacy generally decreases as patients develop treatment resistance. Genetic profiling of melanocytes and the discovery of novel molecular factors involved in the pathogenesis of melanoma have helped to identify new therapeutic targets. In this literature review, we examine several newly approved therapies, and briefly describe several therapies being assessed for melanoma. The goal is to provide a comprehensive overview of recent developments and to consider future directions in the field of melanoma.

Citing Articles

Novel Method for the Synthesis of Hydroxycobalamin[-lactam] and Its Impact on Melanoma Cells In Vitro.

Rzepka Z, Janus M, Marciniec K, Rok J, Wrzesniok D Int J Mol Sci. 2025; 26(4).

PMID: 40004003 PMC: 11855847. DOI: 10.3390/ijms26041540.

Preclinical pharmaco-toxicological screening of biomimetic melanin-like nanoparticles as a potential therapeutic strategy for cutaneous melanoma.

Marcovici I, Chioibas R, Zupko I, Pinzaru I, Moaca A, Ledeti A Front Pharmacol. 2025; 16:1487854.

PMID: 39981176 PMC: 11839674. DOI: 10.3389/fphar.2025.1487854.

Effect of Neutron Radiation on BPA-Loaded Melanoma Spheroids and Melanocytes.

Szczepanek M, Silarski M, Panek A, Telk A, Dziedzic-Kocurek K, Parisi G Cells. 2025; 14(3).

PMID: 39937023 PMC: 11816858. DOI: 10.3390/cells14030232.

Targeting Matrix Metalloproteinases and Their Inhibitors in Melanoma.

Szczygielski O, Dabrowska E, Niemyjska S, Przylipiak A, Zajkowska M Int J Mol Sci. 2025; 25(24.

PMID: 39769318 PMC: 11676509. DOI: 10.3390/ijms252413558.

Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations.

Wang W, Lian B, Xu C, Wang Q, Li Z, Zheng N Innovation (Camb). 2024; 5(6):100661.

PMID: 39529955 PMC: 11551471. DOI: 10.1016/j.xinn.2024.100661.

References

Kawakami Y, Rosenberg S . T-cell recognition of self peptides as tumor rejection antigens. Immunol Res. 1996; 15(3):179-90. DOI: 10.1007/BF02918248. View

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S . Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev. 2003; 29(4):241-52. DOI: 10.1016/s0305-7372(03)00074-4. View

Faramarzi S, Ghafouri-Fard S . Melanoma: a prototype of cancer-testis antigen-expressing malignancies. Immunotherapy. 2017; 9(13):1103-1113. DOI: 10.2217/imt-2017-0091. View

Gasser S, Lim L, Cheung F . The role of the tumour microenvironment in immunotherapy. Endocr Relat Cancer. 2017; 24(12):T283-T295. DOI: 10.1530/ERC-17-0146. View

Gattinoni L, Klebanoff C, Palmer D, Wrzesinski C, Kerstann K, Yu Z . Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest. 2005; 115(6):1616-26. PMC: 1137001. DOI: 10.1172/JCI24480. View

Siddik Z . Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003; 22(47):7265-79. DOI: 10.1038/sj.onc.1206933. View

Beadling C, Jacobson-Dunlop E, Hodi F, Le C, Warrick A, Patterson J . KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008; 14(21):6821-8. DOI: 10.1158/1078-0432.CCR-08-0575. View

. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: A systematic review. Int J Cancer. 2006; 120(5):1116-22. DOI: 10.1002/ijc.22453. View

10.

Fitzgerald M, Harkin D, Silva-Arrieta S, MacDonald D, Lucchina L, Unsal H . Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci U S A. 1996; 93(16):8541-5. PMC: 38708. DOI: 10.1073/pnas.93.16.8541. View

11.

Mattia G, Puglisi R, Ascione B, Malorni W, Care A, Matarrese P . Cell death-based treatments of melanoma:conventional treatments and new therapeutic strategies. Cell Death Dis. 2018; 9(2):112. PMC: 5833861. DOI: 10.1038/s41419-017-0059-7. View

12.

Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Maitre M . Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012; 26 Suppl 3:22-31. DOI: 10.1111/j.1468-3083.2012.04520.x. View

13.

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

14.

Gonzalez D, Fearfield L, Nathan P, Taniere P, Wallace A, Brown E . BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel. Br J Dermatol. 2013; 168(4):700-7. DOI: 10.1111/bjd.12248. View

15.

Albino A, Vidal M, McNutt N, Shea C, Prieto V, Nanus D . Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res. 1994; 4(1):35-45. DOI: 10.1097/00008390-199402000-00006. View

16.

Dong J, Phelps R, Qiao R, Yao S, Benard O, Ronai Z . BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 2003; 63(14):3883-5. View

17.

Jiang B, Zhang L, Guo X, Shen X, Wang Y, Zhu Y . Poly(N-phenylglycine)-Based Nanoparticles as Highly Effective and Targeted Near-Infrared Photothermal Therapy/Photodynamic Therapeutic Agents for Malignant Melanoma. Small. 2016; 13(8). DOI: 10.1002/smll.201602496. View

18.

Stretch J, Gatter K, Ralfkiaer E, Lane D, Harris A . Expression of mutant p53 in melanoma. Cancer Res. 1991; 51(21):5976-9. View

19.

Candido S, Rapisarda V, Marconi A, Malaponte G, Bevelacqua V, Gangemi P . Analysis of the B-RafV600E mutation in cutaneous melanoma patients with occupational sun exposure. Oncol Rep. 2014; 31(3):1079-82. PMC: 3926654. DOI: 10.3892/or.2014.2977. View

20.

Kim K, Li B, Winer J, Armanini M, Gillett N, PHILLIPS H . Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362(6423):841-4. DOI: 10.1038/362841a0. View